Signal Genetics Debuts Gene Expression-Based Prognostic for Multiple Myeloma

The whole-genome assay, called Myeloma Prognostic Risk Signature, or MyPRS, interrogates 70 genes with an internally developed algorithm to help predict a patient’s outcome.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.